Safe Surf Rated Back To Home Page Family Friendly Site
About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV and AIDS News Bradford McIntyre
   



 Canadian Treatment Action Council (CTAC) - www.ctac.ca

Alberta Approves Boceprevir and Telaprevir for People Living with HIV and Viral Hepatitis

When will other provincial formularies follow

December 3, 2012 - Toronto, ON: As of World AIDS Day this year, the Government of Alberta took a major step, approving the use of boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex) - two new medications used as part of a combination therapy[i] to treat Hepatitis C genotype 1(HCV-1) - for all people living with Hepatitis C, including people living with Hepatitis C who are co-infected with HIV.

While boceprevir and telaprevir have been shown to be safe and effective in HCV/HIV co-infected people in phase 3 clinical trials, Alberta's is the first provincial formulary allowing their use with co-infected populations. HCV/HIV co-infection is a serious, life-threatening condition with liver health complications (including liver disease and liver cancer) accelerating decades quicker than in those living with Hepatitis C alone.

"We applaud the Government of Alberta for making the right decision and taking the urgent health needs of Hepatitis C and HIV co-infected people seriously," said Akim Adé Larcher, CTAC's Executive Director. "It's shameful that no other province or territory has approved either drug for co-infected people, despite the evidence."

In November, boceprevir and telaprevir were both awarded the innovative product Prix Galien award. They are the first direct antivirals for the treatment of chronic HCV genotype 1, both of which have substantially increased cure rates for Hepatitis C from 30-50% to 60-80% . CTAC urges all Canadian formularies to expand Hepatitis C treatment access to include boceprevir and telaprevir for all affected patients, regardless of where they live, their financial status or disease progression.

###

For more information please contact:
Akim Adé Larcher,
+1 416-268-1622,
akim@ctac.ca

ABOUT CTAC
The Canadian Treatment Action Council (CTAC) works to secure and ensure access to therapies, treatments and care for people living with HIV/AIDS, including those who are co-infected, by working with the public, private and not-for-profit sectors. For more information on CTAC's mandate, mission and work please visit www.ctac.ca .


"Reproduced with permission - CTAC Canadian Treatment Action Council "

CTAC
www.ctac.ca


For more HIV and AIDS News visit...

Positively Positive - Living with HIV/AIDS:
HIV/AIDS News


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik

Copyright © 2003-2017 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS